Related Experiment Video
Updated: Jul 16, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Src kinase signaling in leukaemia.
1The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA. shaoguang.li@jax.org
The International Journal of Biochemistry & Cell Biology
|March 14, 2007
Summary
Src kinases play a key role in acute lymphoblastic leukaemia (ALL). Inhibiting both BCR-ABL and Src kinases simultaneously offers a promising therapeutic strategy for ALL, including targeting leukaemic stem cells.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Src kinases are implicated in acute lymphoblastic leukaemia (ALL) pathogenesis.
- BCR-ABL oncoprotein drives ALL, but resistance to inhibitors like imatinib is a challenge.
- Leukaemic stem cells (LSCs) are crucial for ALL persistence and relapse.
Purpose of the Study:
- To investigate the role of Src kinases in BCR-ABL-driven ALL.
- To explore the effectiveness of combined BCR-ABL and Src kinase inhibition.
- To understand the mechanisms behind imatinib resistance in Philadelphia chromosome-positive ALL.
Main Methods:
- Utilized a leukaemia mouse model to study ALL.
- Investigated Src kinase activation in leukaemic cells.
- Assessed the impact of simultaneous BCR-ABL and Src kinase inhibition.
Main Results:
- Src kinase activation by BCR-ABL is independent of BCR-ABL kinase activity.
- This independence explains imatinib's reduced effectiveness in Philadelphia chromosome-positive ALL.
- Combined inhibition of BCR-ABL and Src kinases led to long-term survival in mice.
Conclusions:
- Targeting Src kinases alongside BCR-ABL is a potential therapeutic strategy for ALL.
- Overcoming imatinib resistance may involve dual kinase inhibition.
- Eradication of leukaemic stem cells is key for a curative ALL therapy.
Related Concept Videos
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...